Recent Blog Articles
How — and why — to fit more fiber and fermented food into your meals
Tick season is expanding: Protect yourself against Lyme disease
What? Another medical form to fill out?
How do trees and green spaces enhance our health?
A muscle-building obsession in boys: What to know and do
Harvard Health Ad Watch: New drug, old song, clever tagline
Concussion in children: What to know and do
What color is your tongue? What's healthy, what's not?
Your amazing parathyroid glands
When — and how — should you be screened for colon cancer?
Adam S. Cheifetz, MD
Contributor
Dr. Adam Cheifetz is director of the center for inflammatory bowel disease and medical director of infusion services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School. He is a well-recognized leader in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. He is involved in multiple research projects relating to IBD, and has published over 200 articles and chapters on the subject.
His research currently focuses on therapeutic drug monitoring and optimizing the use of biologics through the proactive use of drug concentrations and antibodies, and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care.
Recent Blog Articles
How — and why — to fit more fiber and fermented food into your meals
Tick season is expanding: Protect yourself against Lyme disease
What? Another medical form to fill out?
How do trees and green spaces enhance our health?
A muscle-building obsession in boys: What to know and do
Harvard Health Ad Watch: New drug, old song, clever tagline
Concussion in children: What to know and do
What color is your tongue? What's healthy, what's not?
Your amazing parathyroid glands
When — and how — should you be screened for colon cancer?
